PD-L1 Levels Fail to Predict ALK Inhibitor Benefit in Lung Cancer Cohort
A 129-patient Japanese multicenter study found that tumor PD-L1 expression did not predict the effectiveness of ALK inhibitor therapy in ...
Tag: Targeted therapy
Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case
A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who ...
Belzutifan Shows Radiographic Improvement in Two Sporadic CNS Hemangioblastoma Cases
In a new report published in Frontiers in Oncology, physicians at the Medical College of Wisconsin describe two patients with ...
Aptamers Emerge as Programmable Building Blocks for Precision Cancer Immunotherapy
A new review maps how engineered DNA and RNA aptamers could enable targeted delivery and tumor microenvironment remodeling in precision ...
PAPILLON finds longer survival with amivantamab in rare EGFR lung cancer
Final randomized PAPILLON results found a six-month median overall-survival advantage with amivantamab plus chemotherapy in EGFR exon 20-mutated non-small cell ...
Retrospective study links combined HAIC and systemic therapy to outcomes in advanced liver cancer
A retrospective cohort of 331 initially diagnosed patients with HCC and Vp3/4 portal vein tumor thrombosis found a 61.3% objective ...
Gene Loss Drives Blood Vessel Growth in Aggressive IDH-Mutant Astrocytoma
A study in the Journal of Translational Medicine reports that CDKN2A/B homozygous deletion is associated with increased vascular formation in ...
NRAS mutation renders ovarian cancer cells vulnerable to MEK inhibitor trametinib
Engineered ovarian cancer cell models carrying an activating NRAS mutation showed heightened sensitivity to the MEK inhibitor trametinib, suggesting a ...
HAX1 review highlights context-dependent roles in cancer progression
A 2026 review finds that the molecular scaffold HAX1 supports tumor growth, invasion, hypoxic adaptation and treatment resistance while showing ...
Zipalertinib plus chemotherapy extends survival in EGFR exon 20 lung cancer
In the phase 3 REZILIENT 3 trial, adding zipalertinib to platinum-pemetrexed chemotherapy extended median progression-free survival from 8.5 to 14.5 ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!